Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience
Associations between residual disease and survival in epithelial ovarian cancer by histologic type
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and non-invasive low-grade carcinomas: a population-based clinicopathologic study of 942 cases
Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma
Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors
Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer
Previous
Previous
2018
Next
Next